Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio

Now watching

Next video starts in : 7 Play

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio
Replay video
Up next

What to Watch Thursday: P&G and Mondelez Earnings, GDP Report

Unlock your personal NFL Now stream by signing in to NFL.com

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio

by TheStreet 1:57 mins

Roche Buys Seragon for $1.7 Billion, Widening Its Cancer Portfolio

by TheStreet 1:57 mins

Swiss drugmaker Roche Group announced it would buy Seragon Pharmaceuticals for $1.7 billion. It's the latest in a series of acquisitions for Roche, which bought Genia Technologies in June for $350 million and IQuum in May for $450 million. The Deal correspondent Andrew Bulkeley explains how Seragon's portfolio, which includes a focus on treatments for breast cancer, will impact Roche and its subsidiary Genentech going forward. Also, as the company widens its offerings of cancer treatments, Bulkeley reveals what other holes it may have in its portfolio and what other acquisitions it may make down the road.

TheStreet

Investing

Market Movers